Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study

OBJECTIVE: CT-P13 is a biosimilar with comparable pharmacokinetics, efficacy and safety to its reference product (RP), infliximab. Studies have shown that switching from RP to CT-P13 does not reduce the effectiveness or safety of treatment. METHODS: In this retrospective real-world study, patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergara-Dangond, Cristina, Sáez Belló, Marina, Climente Martí, Mónica, Llopis Salvia, Pilar, Alegre-Sancho, Juan José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629134/
https://www.ncbi.nlm.nih.gov/pubmed/28667384
http://dx.doi.org/10.1007/s40268-017-0194-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629134/
https://www.ncbi.nlm.nih.gov/pubmed/28667384
http://dx.doi.org/10.1007/s40268-017-0194-8

Ejemplares similares